EMA explains when to use active controls in clinical trials
This article was originally published in SRA
Executive Summary
The European Medicines Agency has issued a draft reflection paper explaining when drug companies should make use of active control in clinical trials. The scope of the paper is restricted to therapeutic areas where the use of a placebo is deemed ethical and one or more established medicines are available1,2.